Our colleagues at Start-Up do a little thing every year they call The A-List , in which they slice, dice, julienne and slow-cook the year...

The year is nearly one-fourth done. Is it just In Vivo Blog, or is life speeding up? For those with small children and caffeine addictions, ...

Fate Therapeutics has lined up $30 million in a Series B venture round as it pushes development of its lone clinical candidate, works toward...

What if this is the best thing that could have happened for venture capitalists and their companies? By “this” we mean the complete and utte...

The announcement that Covidien Ltd. launched a venture fund should come as no surprise to faithful IN VIVO readers. We reported on the gro...

KPMG LLC released a survey this week declaring that a venture capitalist don't expect to see a "consistent flow" of IPOs until...

When we wrote about CardioNet's IPO back in March, we had no idea it would hold such historical importance . CardioNet, trading under t...

That's the thing about Asian venture capital news. A week later and you find yourself still hungry for more. Well, last week we profiled...

This week brought on a flurry of news reports about venture capital firms setting out to raise new funds. VentureWire Lifescience reported ...

Is Kleiner Perkins Caufield & Byers ( KPCB ) evolving into a franchise? Over the past few years, the venture firm has attached its ve...

Tired of Sirtris-GSK talk yet? Too bad. As we now bring you, the venture angle. As you no doubt know by now, GlaxoSmithKline will pay $725 m...

A year ago or so IN VIVO Blog thought we had a pretty good scoop. While we were writing this piece on specialized health care funds, we he...

IN VIVO Blog tries not to get too wrapped up in the value of quarterly numbers. Honestly, what exactly does three months of data tell you o...

Remain calm. All is... Well, not so good. The start of April means one thing and one thing only. Well, okay actually it means several things...